» Articles » PMID: 23787903

QT Variability During Initial Exposure to Sotalol: Experience Based on a Large Electronic Medical Record

Overview
Journal Europace
Date 2013 Jun 22
PMID 23787903
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: A prolonged QT interval is associated with increased risk of Torsades de pointes (TdP) and may be fatal. We sought to investigate the extent to which clinical covariates affect the change in QT interval among 'real-world' patients treated with sotalol and followed in an electronic medical record (EMR) system.

Methods And Results: We used clinical alerts in our EMR system to identify all patients in whom a new prescription for sotalol was written (2001-11). Rate-corrected QT (QTc) was calculated by Bazett's formula. Correlates of sotalol-induced change in the QTc interval and sotalol discontinuation were examined using linear and logistic regression, respectively. Overall, 541 sotalol-exposed patients were identified (n = 200 women, 37%). The mean first sotalol dose was 86 ± 39 mg, age 64 ± 13 years, and BMI 30 ± 7 kg/m(2). Atrial fibrillation/flutter was the predominant indication (92.2%). After initial exposure, the change in the QTc interval from baseline was highly variable: ΔQTc after 2 h = 3 ± 42 ms (P = 0.17) and 11 ± 37 ms after ≥48 h (P < 0.001). Multivariable linear regression analysis identified female gender and age, reduced left ventricular ejection fraction, high sotalol dose, hypertrophic cardiomyopathy, and loop diuretic co-administration as correlates of increased ΔQTc at ≥48 h (P < 0.05 for all). Within 3 days of initiation, 12% discontinued sotalol of which 31% were because of exaggerated QTc prolongation. One percent developed TdP.

Conclusion: In this EMR-based cohort, the increase in QTc with sotalol initiation was highly variable, and multiple clinical factors contributed. These data represent an important step in ongoing work to identify real-world patients likely to tolerate long-term therapy and reinforces the utility of EMR-based cohorts as research tools.

Citing Articles

Sex and Gender Differences in Ventricular Arrhythmias.

Warnock R, Modi R, Westerman S US Cardiol. 2024; 17:e12.

PMID: 39559519 PMC: 11571389. DOI: 10.15420/usc.2022.38.


Long QT Syndrome With Drugs Used in the Management of Arrhythmias: A Systematic Review.

Khan S, Emmanuel S, Shantha Kumar V, Nerella R, Shaman Ameen B, Patel D Cureus. 2024; 16(7):e65857.

PMID: 39219930 PMC: 11364149. DOI: 10.7759/cureus.65857.


Safety of outpatient commencement of sotalol.

Kamsani S, Middeldorp M, Chiang G, Stefil M, Evans S, Nguyen M Heart Rhythm O2. 2024; 5(6):341-350.

PMID: 38984365 PMC: 11228273. DOI: 10.1016/j.hroo.2024.05.003.


Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.

Premuzic Mestrovic I, Smoday I, Kalogjera L, Krezic I, Zizek H, Vranes H Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513889 PMC: 10383471. DOI: 10.3390/ph16070977.


Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.

Lenhoff H, Darpo B, Page A, Couderc J, Tornvall P, Frick M Ann Noninvasive Electrocardiol. 2021; 26(4):e12834.

PMID: 33629473 PMC: 8293609. DOI: 10.1111/anec.12834.


References
1.
Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D . Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287(17):2215-20. DOI: 10.1001/jama.287.17.2215. View

2.
Chung M, Schweikert R, Wilkoff B, Niebauer M, Pinski S, Trohman R . Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol. 1998; 32(1):169-76. DOI: 10.1016/s0735-1097(98)00189-2. View

3.
Choy A, Darbar D, DellOrto S, Roden D . Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol. 1999; 34(2):396-401. DOI: 10.1016/s0735-1097(99)00226-0. View

4.
Davey P, Barlow C, Hart G . Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clin Sci (Lond). 2000; 98(5):603-10. View

5.
Roden D . Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350(10):1013-22. DOI: 10.1056/NEJMra032426. View